Regulatory and Clinical Outcomes of Nononcology Accelerated Approvals.
作者信息
Liu Ian T T, Reynolds Gemma, Kesselheim Aaron S, Cliff Edward R Scheffer
机构信息
Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Pediatrics, University of Illinois at Chicago.
出版信息
JAMA. 2025 Jul 14. doi: 10.1001/jama.2025.10726.
Abstract
摘要
相似文献
1
Regulatory and Clinical Outcomes of Nononcology Accelerated Approvals.非肿瘤学加速批准的监管与临床结果
JAMA. 2025 Jul 14. doi: 10.1001/jama.2025.10726.
2
Comparison of drug approvals of the FDA and EMA between 2013 and 2023.2013年至2023年美国食品药品监督管理局（FDA）与欧洲药品管理局（EMA）药品批准情况的比较。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 3. doi: 10.1007/s00210-025-04412-4.
3
A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational Study.2023年美国食品药品监督管理局批准的抗癌药物和生物制品综述：一项观察性研究
J Pharm Bioallied Sci. 2025 Jan-Mar;17(1):27-32. doi: 10.4103/jpbs.jpbs_730_25. Epub 2025 Jun 18.
4
How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease.美国食品药品监督管理局（FDA）监管流程和程序的改进如何促成了有史以来第一种常见肝脏疾病治疗药物的获批。
Acta Pharmacol Sin. 2025 Mar;46(3):515-524. doi: 10.1038/s41401-024-01396-4. Epub 2024 Nov 7.
5
Real-World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020-2022.2020 - 2022财年新药和生物制品许可申请批准中的真实世界证据
Clin Pharmacol Ther. 2025 Jul;118(1):85-89. doi: 10.1002/cpt.3688. Epub 2025 Apr 25.
6
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.PD-1/PD-L1 抑制剂在肿瘤学中的系统评价：从个性化医疗到公共卫生。
Oncologist. 2021 Oct;26(10):e1786-e1799. doi: 10.1002/onco.13887. Epub 2021 Jul 27.
7
US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.美国食品和药物管理局在 1992 年至 2018 年间对非肿瘤药物适应症的加速审批计划。
JAMA Netw Open. 2022 Sep 1;5(9):e2230973. doi: 10.1001/jamanetworkopen.2022.30973.
8
A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.真实世界证据（RWE）在罕见病新药和生物制品申请批准中的系统评价
Orphanet J Rare Dis. 2024 Mar 12;19(1):117. doi: 10.1186/s13023-024-03111-2.
9
Has FDA's Drug Development Tools Qualification Program Improved Drug Development?美国食品药品监督管理局（FDA）的药物开发工具资格认定计划是否改进了药物研发？
Ther Innov Regul Sci. 2025 May 4. doi: 10.1007/s43441-025-00790-2.
10
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.2005 - 2014年美国支持处方药补充适应症获批的疗效证据特征：系统评价
BMJ. 2015 Sep 23;351:h4679. doi: 10.1136/bmj.h4679.
本文引用的文献
1
Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.神经丝轻链：一种处于基因导向治疗的清晰与困惑交叉点的生物标志物。
Neurodegener Dis Manag. 2024;14(6):227-239. doi: 10.1080/17582024.2024.2421738. Epub 2024 Nov 15.
2
Sickle cell drug is withdrawn over safety concerns just months after rollout.镰状细胞病药物在推出仅几个月后就因安全担忧而被撤市。
BMJ. 2024 Oct 1;387:q2147. doi: 10.1136/bmj.q2147.
3
Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments.替代标志物与非肿瘤慢性疾病治疗的临床结局之间的关联。
JAMA. 2024 May 21;331(19):1646-1654. doi: 10.1001/jama.2024.4175.
4
Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.癌症药物加速审批的临床获益和监管结果。
JAMA. 2024 May 7;331(17):1471-1479. doi: 10.1001/jama.2024.2396.
5
Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022.分析美国食品和药物管理局新药和生物制剂批准情况、监管途径和审查时间，1980-2022 年。
Sci Rep. 2024 Feb 9;14(1):3325. doi: 10.1038/s41598-024-53554-7.
6
The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence.基于有限证据批准肌肉萎缩症药物的监管后果。
Ann Intern Med. 2023 Sep;176(9):1251-1256. doi: 10.7326/M23-1073. Epub 2023 Aug 22.
Zotero 插件